A Phase II/III trial of PMZ-1620, as a diagnostic imaging agent, for imaging of solid tumors.

Trial Profile

A Phase II/III trial of PMZ-1620, as a diagnostic imaging agent, for imaging of solid tumors.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs PMZ 1620 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top